Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554600 | 0.95 | F10 (0.38) | F10ITGB3ITGA2BF2ROCK2 | |
| SCHEMBL7564564 | 0.89 | ROCK2 (0.38) | F10ITGB3ITGA2BF2ROCK2 | |
| SCHEMBL6556848 | 0.89 | F10 (0.48) | F10ITGB3ITGA2BF2ROCK2 | |
| SCHEMBL6556709 | 0.88 | ALDH1A1 (0.39) | F10ITGB3ITGA2BF2ROCK2 | |
| Hydrochloric Acid SCHEMBL6554772 | 0.88 | F10 (0.47) | F10ITGB3ITGA2BF2ROCK2 | |
| SCHEMBL7566309 | 0.82 | F10 (0.49) | F10ITGB3ITGA2BF2ROCK2 | |
| Hydrochloric Acid SCHEMBL6554519 | 0.82 | F10 (0.48) | F10ITGB3ITGA2BF2ROCK2 | |
| SCHEMBL7560948 | 0.82 | F10 (0.47) | F10ITGB3ITGA2BF2ROCK2 | |
| SCHEMBL7560045 | 0.82 | F10 (0.46) | F10ITGB3ITGA2BF2ROCK2 | |
| Hydrochloric Acid SCHEMBL6554506 | 0.81 | F10 (0.45) | F10ITGB3ITGA2BF2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | F10 35/4885ITGB3 108/4885ITGA2B 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.